PUL-042 Inhalation Solution

DRUG5 trials

Sponsors

Pulmotect, Inc.

Conditions

COPDCOVID-19Healthy

Phase 1

Safety and Tolerability of Single Ascending Doses of PUL-042 Inhalation Solution in Healthy Subjects

CompletedNCT02124278

Pulmotect, Inc.Healthy

Start: 2014-02-28End: 2014-10-31Updated: 2015-04-29

Effect of Pre-Treatment With Cromolyn or Albuterol on Response to PUL-042 Inhalation Solution (PUL-042)

CompletedNCT02566252

Pulmotect, Inc.Healthy

Start: 2015-07-31End: 2016-03-31Updated: 2017-08-10

Phase 2

The Effect of Inhaled PUL-042 on Rhinovirus-induced Symptoms in Smokers With GOLD Stage 0 COPD

CompletedNCT03794557

Pulmotect, Inc.COPD

Start: 2019-01-21End: 2021-03-23Updated: 2021-06-01

The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2

CompletedNCT04313023

Pulmotect, Inc.COVID-19

Start: 2020-06-09End: 2021-07-31Updated: 2023-05-17

The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection

CompletedNCT04312997

Pulmotect, Inc.COVID-19

Start: 2020-06-16End: 2021-07-02Updated: 2023-04-18